

**TTY BIOPHARM<sup>®</sup>**

台灣東洋藥品

WELCOME TO JOIN US

2022年度  
永續報告書摘要



# 永續策略

關鍵績效

亮點表現


ISO 認證

## 2022 Sustainability Report



東洋藥品


永續報告書



TTY Biopharm  
Company Limited

# TTY 永續策略

## 台灣東洋藥品 ESG 策略藍圖



# 2022 年度 關鍵績效

## 經營面向



- 2022年合併營收達新台幣**50.61億元** (自2015至2022營收年複合成長率達**6.79%**)
- 專注研發製造代工，微脂體困難學名藥Lipo-AB成功進入美國市場
- 完善重症疫苗和麻醉領域產品線
- 腫瘤新藥共**3項**將成為企業的成長引擎
- 截至2022年底，已核准仍有效的發明專利共**7件** (審查中的發明專利申請1件)
- 再度得標公費流感疫苗，2022年共供應公費疫苗**113萬劑**及自費疫苗**23萬劑**

# 2022 年度 關鍵績效

## 產品概況



- 2022年共取得**130張**藥品許可證
- 2022年，逾**36個**藥品品項被列入台灣全民健康保險藥物給付項目
- 截至2022年底，已核准仍有效的發明專利共**7件**，審查中的發明專利申請共**1件**
- 截至2022年底，已核准註冊的商標共**211件**，審查中的商標申請共**13件**
- 遵行「國際PIC/S GMP製藥標準」及「優良藥品運銷規範」提供100%合規之試驗藥品

# 2022 年度 關鍵績效

## 公司治理 (Governance)



- 連續7年榮獲台灣證交所公司治理評鑑上櫃公司排名**前5%**
- 2022年董事會共開會**6次**，出席率**98.15%**（未含委託出席）
- 2022年董事會成員進修時數平均達**9.94小時**
- 董事會成員含**2位**女性董事、**3位**獨立董事，展現多元且獨立的治理文化
- 2022年薪資報酬委員會共開會**2次**，成員平均出席率**100%**（未含委託出席）
- 2022年審計委員會共開會**5次**，成員出席率**100%**（未含委託出席）

# 2022 年度 關鍵 績效

## 環境友善 (Environmental)



- 六堵廠與中壢廠透過8項節電措施 **節電163,225.93度、減排83.08tonCO<sub>2</sub>e**。
- 六堵廠放流水所含COD值遠低於當地法規納管標準 **22.83倍**
- 六堵廠放流水所含SS值遠低於當地法規納管標準 **98.36倍**
- 中壢廠放流水所含COD值遠低於當地法規納管標準 **19.80倍**
- 中壢廠放流水所含SS值遠低於當地法規納管標準 **43.24倍**
- 中壢廠、六堵廠查核廢棄物清運廠商每週及每月勾稽達成率 **100%**

# 2022 年度關鍵績效

## 社會參與 (Social)



- 2022年新進員工**64名**，共提供**521個**就業機會
- 女性擔任經理級以上的關鍵領導職務為**42.19%**，實現性別平等的職場
- 2022年基層人員平均薪資較當地最低薪資高逾**1.5倍**
- 2022年每名員工受訓平均時數**6.82小時**
- 2022年提供**632名**員工及其眷屬免費施打流感疫苗
- 連續15年舉辦暑期實習專案，累計受惠人數達**391名**學生

# 亮點表現

- ◆ 為深化永續發展資訊揭露，台灣東洋依據GRI準則，並強化氣候相關財務揭露(TCFD)及SASB行業準則之指標，公佈公司治理及推動永續發展執行情形。
- ◆ 倡議聯合國17項永續發展目標SDGs項目包括：1.消除貧窮、3.健康與福祉、4.教育品質、6.淨水與衛生、8.就業與經濟成長、9.工業/創新與基礎建設、12.責任消費與生產、13.氣候行動、16.和平與正義制度、與17.全球夥伴，為2022年達成的發展方向。
- ◆ 2022年獲「Health 2.0 論壇」評為「年度傑出醫療保健公司」(Best Companies in the healthcare industry)，以及，暨2020年再度取得亞太區知名人力資源雜誌《HR Asia》肯定，頒予「2022亞洲最佳企業雇主獎」(Best Companies to Work for in Asia 2022 Taiwan Edition)。同時於2021年及2022年，連續2年榮獲TCSA台灣企業永續獎之醫療保健類白金獎。

# ISO 認證

## ISO 45001

Certificate No.: 010-23043-O

# Certificate of Approval

This is to certify that the Occupational Health & Safety Management System

**台灣東洋藥品工業股份有限公司**

TTY Biopharm Company Limited

3F., No. 3-1, Park St., Nangang Dist., Taipei City, Taiwan (R.O.C.)  
No.838, Sec. 1, Zhonghua Rd., Zhongli Dist, Taoyuan City, Taiwan (R.O.C.)

### ISO 45001:2018

驗證範圍

西藥製造、分包裝、實驗室及運銷作業

Pharmaceutical manufacturing, packaging, laboratory and  
Distribution business

證書生效日期12/30/2022，有效期至12/29/2023 \*

  
**Sanjay Kaushik**  
 Managing Director

  
**QMS**

  
**JAS-ANZ**

QMS Certification Services Pvt. Ltd.  
 Affil-1, Sitapur Enclave, 47,  
 Reghendra Colony,  
 Vishwanthpur, Bangalore - 560 022,  
 Karnataka, INDIA  
 e-mail: qmscsp@qmsc.com

\* Subject to compliance with requirements specified in Service Specification & Agreement  
 \* To check the validity of this certificate please visit www.jas-anz.org/registrant

APPROVED BY: MMS/010/18

Occupational Health & Safety Management System

## ISO 14064-1

### Independent Assurance Opinion

Verification Opinion No.: C601645-2022-AG-TWN-DNV    Issued date: 7 June, 2023    Page 1 of 2

This is to verify initiate reporting of Greenhouse Gas Inventory Management Report (2022) of

### TTY Biopharm Company Limited

**Scope of Verification**  
 DNV Business Assurance (DNV) has been commissioned by TTY Biopharm Company Limited (the Organization) to perform a verification of the greenhouse gas statements of Greenhouse Gas Inventory Management Report (2022) (hereafter the "Inventory Report") in Taiwan, ROC with respect to the sites listed in Appendix A.  
 The Reporting Boundary for the verification including direct GHG emissions and removals, indirect GHG emissions from imported energy, indirect GHG emissions from transportation, and indirect GHG emissions from products used by the Organization. The further descriptions for the Reporting Boundary listed in Appendix B.


**Verification Criteria and GHG Programme**  
 The verification was performed on the basis of ISO 14064-1:2018 as well as criteria given to provide for consistent GHG emission identification, calculation, monitoring and reporting. The verification was conducted in accordance with ISO 14066:2011, ISO 14065:2020, ISO14064-3:2019

**Verification Opinion**  
 It is DNV's opinion that the Inventory Report (2022), which was published on May 29, 2023 (Ver. 1), is free from material discrepancies in accordance with the verification criteria identified as stated above. The opinion is decided based on the following approaches:  
 - For the Direct (Category 1) and Indirect GHG emissions from imported energy (Category 2), the reliability of the information within the Inventory Report (2022) were verified with reasonable level of assurance.  
 - For the other indirect GHG emissions, the involved information was verified and tested using agreed-upon procedures, AUP, defined in Inventory Report.

Alvin Chen

  
 Place and date:  
 Taipei, 7 June, 2023

For the issuing office:  
**DNV Business Assurance Co., Ltd.**  
 2391, No. 293, Sec. 2, Wanhua Rd.,  
 Banqiao District, New Taipei City  
 220, Taiwan

  
 Management Representative

Lack of fulfillment of conditions as set out in the Certification Agreement may render this Certificate Invalid. The Verification Opinion is based on the information made available to us and the engagement conditions detailed above. Hence, DNV cannot guarantee the accuracy or correctness of the information. DNV cannot be held liable by any party relying or acting upon this Verification Opinion.

DNV ZMATW-CP-F50, Rev.10, 2023-2

Category	Emissions (tCO <sub>2</sub> e)	Removals (tCO <sub>2</sub> e)	Net Emissions (tCO <sub>2</sub> e)
Scope 1	1,535.3169	-	1,535.3169
Scope 2	2,232.4903	-	2,232.4903
Scope 3	2,767.8072	-	2,767.8072
Scope 4	1,215.7928	-	1,215.7928
Scope 5	1,744.7213	-	1,744.7213
Scope 6	81.4213	-	81.4213
Scope 7	3,041.9354	-	3,041.9354
Scope 8	2,809.7426	-	2,809.7426
Scope 9	-	-	-
Scope 10	-	-	-
Scope 11	-	-	-
Scope 12	-	-	-
Scope 13	-	-	-
Scope 14	-	-	-
Scope 15	-	-	-
Scope 16	-	-	-
Scope 17	-	-	-
Scope 18	-	-	-
Scope 19	-	-	-
Scope 20	-	-	-
Scope 21	-	-	-
Scope 22	-	-	-
Scope 23	-	-	-
Scope 24	-	-	-
Scope 25	-	-	-
Scope 26	-	-	-
Scope 27	-	-	-
Scope 28	-	-	-
Scope 29	-	-	-
Scope 30	-	-	-
Scope 31	-	-	-
Scope 32	-	-	-
Scope 33	-	-	-
Scope 34	-	-	-
Scope 35	-	-	-
Scope 36	-	-	-
Scope 37	-	-	-
Scope 38	-	-	-
Scope 39	-	-	-
Scope 40	-	-	-
Scope 41	-	-	-
Scope 42	-	-	-
Scope 43	-	-	-
Scope 44	-	-	-
Scope 45	-	-	-
Scope 46	-	-	-
Scope 47	-	-	-
Scope 48	-	-	-
Scope 49	-	-	-
Scope 50	-	-	-
Scope 51	-	-	-
Scope 52	-	-	-
Scope 53	-	-	-
Scope 54	-	-	-
Scope 55	-	-	-
Scope 56	-	-	-
Scope 57	-	-	-
Scope 58	-	-	-
Scope 59	-	-	-
Scope 60	-	-	-
Scope 61	-	-	-
Scope 62	-	-	-
Scope 63	-	-	-
Scope 64	-	-	-
Scope 65	-	-	-
Scope 66	-	-	-
Scope 67	-	-	-
Scope 68	-	-	-
Scope 69	-	-	-
Scope 70	-	-	-
Scope 71	-	-	-
Scope 72	-	-	-
Scope 73	-	-	-
Scope 74	-	-	-
Scope 75	-	-	-
Scope 76	-	-	-
Scope 77	-	-	-
Scope 78	-	-	-
Scope 79	-	-	-
Scope 80	-	-	-
Scope 81	-	-	-
Scope 82	-	-	-
Scope 83	-	-	-
Scope 84	-	-	-
Scope 85	-	-	-
Scope 86	-	-	-
Scope 87	-	-	-
Scope 88	-	-	-
Scope 89	-	-	-
Scope 90	-	-	-
Scope 91	-	-	-
Scope 92	-	-	-
Scope 93	-	-	-
Scope 94	-	-	-
Scope 95	-	-	-
Scope 96	-	-	-
Scope 97	-	-	-
Scope 98	-	-	-
Scope 99	-	-	-
Scope 100	-	-	-



2022  
Sustainability  
Report

Thank you!

